Immunovant, Inc. (IMVT) Press Releases https://www.immunovant.com/investors/news-events/press-releases/rss en-us https://d1io3yog0oux5.cloudfront.net/_d6ae8ad1fc90c30ceeec0c8ff3e3b1be/immunovant/files/theme/images/logo-sm.jpg Immunovant, Inc. Logo /investors Equisolve Investor Relations Suite <![CDATA[Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)]]> https://www.immunovant.com/investors/news-events/press-releases/detail/81/immunovant-announces-phase-3-study-results-for-batoclimab Thu, 02 Apr 26 05:00:00 -0400 https://www.immunovant.com/investors/news-events/press-releases/detail/81/immunovant-announces-phase-3-study-results-for-batoclimab <![CDATA[Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025]]> https://www.immunovant.com/investors/news-events/press-releases/detail/80/immunovant-provides-corporate-updates-and-reports-financial Fri, 06 Feb 26 07:00:00 -0500 https://www.immunovant.com/investors/news-events/press-releases/detail/80/immunovant-provides-corporate-updates-and-reports-financial <![CDATA[Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026]]> https://www.immunovant.com/investors/news-events/press-releases/detail/79/immunovant-to-report-financial-results-for-the-third Fri, 23 Jan 26 17:25:00 -0500 https://www.immunovant.com/investors/news-events/press-releases/detail/79/immunovant-to-report-financial-results-for-the-third <![CDATA[Immunovant Announces Pricing of $550 Million Common Stock Financing]]> https://www.immunovant.com/investors/news-events/press-releases/detail/78/immunovant-announces-pricing-of-550-million-common-stock Thu, 11 Dec 25 01:29:00 -0500 https://www.immunovant.com/investors/news-events/press-releases/detail/78/immunovant-announces-pricing-of-550-million-common-stock <![CDATA[Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025]]> https://www.immunovant.com/investors/news-events/press-releases/detail/77/immunovant-provides-corporate-updates-and-reports-financial Mon, 10 Nov 25 07:00:00 -0500 https://www.immunovant.com/investors/news-events/press-releases/detail/77/immunovant-provides-corporate-updates-and-reports-financial <![CDATA[Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025]]> https://www.immunovant.com/investors/news-events/press-releases/detail/76/immunovant-to-report-financial-results-for-the-second Mon, 27 Oct 25 16:10:00 -0400 https://www.immunovant.com/investors/news-events/press-releases/detail/76/immunovant-to-report-financial-results-for-the-second <![CDATA[Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients]]> https://www.immunovant.com/investors/news-events/press-releases/detail/75/immunovant-unveils-durability-and-treatment-free-six-month Wed, 03 Sep 25 12:57:00 -0400 https://www.immunovant.com/investors/news-events/press-releases/detail/75/immunovant-unveils-durability-and-treatment-free-six-month <![CDATA[Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025]]> https://www.immunovant.com/investors/news-events/press-releases/detail/74/immunovant-provides-corporate-updates-and-reports-financial Mon, 11 Aug 25 07:00:00 -0400 https://www.immunovant.com/investors/news-events/press-releases/detail/74/immunovant-provides-corporate-updates-and-reports-financial <![CDATA[Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025]]> https://www.immunovant.com/investors/news-events/press-releases/detail/73/immunovant-provides-corporate-updates-and-reports-financial Thu, 29 May 25 07:00:00 -0400 https://www.immunovant.com/investors/news-events/press-releases/detail/73/immunovant-provides-corporate-updates-and-reports-financial <![CDATA[Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402]]> https://www.immunovant.com/investors/news-events/press-releases/detail/72/immunovant-announces-next-phase-of-growth-with-roivant Mon, 21 Apr 25 07:00:00 -0400 https://www.immunovant.com/investors/news-events/press-releases/detail/72/immunovant-announces-next-phase-of-growth-with-roivant